Preventing recurrent respiratory-related hospitalisations in young Indigenous children through regular azithromycin: a multi-centre randomised controlled trial

急性下呼吸道感染（ALRI）是澳大利亚和新西兰土著儿童住院的主要原因。我们的国际、多中心、随机对照试验将确定每周一次阿奇霉素治疗12个月是否能减少土著儿童的ALRI住院率和未来的支气管扩张。我们还将确定阿奇霉素对ALRI率、安全性、抗生素耐药性、对上呼吸道细菌的影响以及成本效益的影响。

Acute lower respiratory infections (ALRI) are a leading cause of hospitalisation in Indigenous children of Australia and New Zealand. Our international, multi-centre, randomised controlled trial will determine whether weekly azithromycin for 12-months, reduces ALRI-hospitalisations and future bronchiectasis among Indigenous children. We will also determine the impact of azithromycin on ALRI rates, safety, antibiotic resistance, impact on the upper airway bacteria, and cost-effectiveness.